# A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

> **NCT07593820** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Gastric Cancer
- Metastatic Breast Cancer
- Endometrial Cancer Metastatic

## Interventions

- **BIOLOGICAL:** p95HER2.CAR-TECH2Me

## Key facts

- **NCT ID:** NCT07593820
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2030-06-01
- **Final completion:** 2041-04-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593820, "A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07593820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*